One-year dynamics of antibody titers after three doses of SARS-CoV-2 BNT162b2 vaccine

Ori Wand, Anna Breslavsky, Amir Bar-Shai, Chezy Levy, Shlomo Maayan, Avi Rimler, Moatasem Zwahra, Keren Cohen-Hagai, Alma Harish, Nadav Zacks, Natalya Bilenko

Research output: Contribution to journalArticlepeer-review

Abstract

Background: A third dose of the BNT162b2 SARS-CoV-2 vaccine leads to a significant increase in antibody levels, however, concerns regarding the long-term persistence of this response exist. We assessed the humoral response for one year following vaccination. Methods: A prospective study among immunocompetent healthcare workers (HCW) who received three doses of BNT162b2. anti-spike antibody titers were measured at six predefined timepoints, from before the second vaccine dose, and up to one year afterwards, which is 4–6 months after the third dose. HCW with a history of SARS-CoV-2 infection were excluded. Results: Seventy-six HCW had all the six serological measurements. Antibody titers significantly increased shortly following the third vaccine dose, and while declining, remained higher from all previous measurements for up to six months. Conclusions: A third dose of BNT162b2 leads to a profound humoral response, which remains significantly higher than previous measurements, even after 6 months.

Original languageEnglish
Pages (from-to)871-874
Number of pages4
JournalVaccine
Volume41
Issue number4
DOIs
StatePublished - 23 Jan 2023

Keywords

  • COVID-19
  • Humoral response
  • Pfizer-BioNTech vaccine
  • SARS-CoV-2
  • Vaccination

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology (all)
  • Veterinary (all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'One-year dynamics of antibody titers after three doses of SARS-CoV-2 BNT162b2 vaccine'. Together they form a unique fingerprint.

Cite this